RetinalGenix Technologies Inc. (RTGN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Research and development | - | - | 102,977 | 82,926 |
| Stock-based compensation | 250,189 | 231,933 | 296,256 | 211,009 |
| Research and development | 14,430 | 13,214 | - | - |
| General and administrative | 383,729 | 341,203 | 244,098 | 368,738 |
| Total operating expenses | 648,348 | 586,350 | 643,331 | 662,673 |
| Interest expense, net | 1,070 | 909 | 960 | 960 |
| Net loss | -649,418 | -587,259 | -644,291 | -663,633 |
| Net loss per share, basic | -0.034 | -0.03 | -0.04 | -0.04 |
| Net loss per share, diluted | -0.034 | -0.03 | -0.04 | -0.04 |
| Weighted average number of common shares outstanding during the period- basic | 18,326,587 | 18,522,295 | 17,970,120 | 17,863,564 |
| Weighted average number of common shares outstanding during the period- diluted | 18,326,587 | 18,522,295 | 17,970,120 | 17,863,564 |